pindolol has been researched along with Adrenal Cortex Cancer in 2 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olson, MF | 2 |
| Tsao, J | 2 |
| Pon, DJ | 2 |
| Schimmer, BP | 2 |
2 other studies available for pindolol and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Agonist-induced desensitization of adenylyl cyclase in Y1 adrenocortical tumor cells.
Topics: Adenylyl Cyclases; Adrenal Cortex Neoplasms; Adrenergic beta-Agonists; Adrenocorticotropic Hormone; | 1991 |
Regulation of adenylyl cyclase activity by beta-adrenergic agonists in a desensitization-resistant mutant cell line.
Topics: Adenylyl Cyclases; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Animals; Gene Expression; | 1991 |